The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors

Autor: Hazem Ghebeh, Shamayel Mohammed, Abeer Al-Omair, Amal Qattant, Cynthia Lehe, Ghofran Al-Qudaihi, Naser Elkum, Mohamed Alshabanah, Suad Bin Amer, Asma Tulbah, Dahish Ajarim, Taher Al-Tweigeri, Said Dermime
Jazyk: angličtina
Rok vydání: 2006
Předmět:
Zdroj: Neoplasia: An International Journal for Oncology Research, Vol 8, Iss 3, Pp 190-198 (2006)
Druh dokumentu: article
ISSN: 1476-5586
1522-8002
DOI: 10.1593/neo.05733
Popis: B7-H1 molecule increases the apoptosis of tumorreactive T lymphocytes and reduces their immunogenicity. Breast cancer is the second most common cause of mortality after lung cancer. Direct evidence linking B7-H1 with cancer has been shown in several malignancies; however, its expression in breast cancer has not been investigated. We used immunohistochemistry to investigate the expression of the B7-H1 molecule in 44 breast cancer specimens and to study its correlation with patients' clinicopathological parameters. The expression of B7-H1 was shown in 22 of 44 patients and was not restricted to the tumor epithelium (15 of 44, 34% in tumor cells), but was also expressed by tumor-infiltrating lymphocytes (TIL; 18 of 44, 41%). Interestingly, intratumor expression of B7-H1 was significantly associated with histologic grade IIInegative (P = .012), estrogen receptor-negative (P = .036), and progesterone receptor-negative (P = .040) patients. In addition, the expression of B7-H1 in TIL was associated with large tumor size (P = .042), histologic grade III (P=.015), positivity of Her2/neu status (P=.019), and severe tumor lymphocyte infiltration (P = .001). Taken together, these data suggest that B7-H1 may be an important risk factor in breast cancer patients and may represent a potential immunotherapeutic target using monoclonal antibody against the B7-H1 molecule.
Databáze: Directory of Open Access Journals